EDGEWISE THERAPEUTICS INC

EWTX04 Dec 2024
Healthcare
$31.34
+0.01 (+1.33%)
Lowest Today
$30.89
Highest Today
$32.26
Today’s Open
$31.34
Prev. Close
$31.54
52 Week High
$38.12
52 Week Low
$6.44
To Invest in EDGEWISE THERAPEUTICS INC

EDGEWISE THERAPEUTICS INC

Healthcare
EWTX04 Dec 2024
+0.01 (+1.33%)
1M
3M
6M
1Y
5Y
Low
$30.89
Day’s Range
High
$32.26
30.89
52 Week Low
$6.44
52-Week Range
52 Week High
$38.12
6.44
1 Day
-
1 Week
-0.74%
1 month return
-7.55%
3 month return
+78.03%
6 month return
+83.24%
1 Year return
+392.9%
3 Years return
+72.55%
5 Years return
-
10 Years return
-
Institutional Holdings
Orbimed Advisors, LLC
15.86
RA Capital Management, LLC
9.41
BlackRock Inc
6.35
Baker Bros Advisors LP
6.17
Novo A/S
5.86
HHG PLC
4.81
Vanguard Group Inc
4.77

Market Status

Fundamentals
Market Cap
2986.48 mln
PB Ratio
6.11
PE Ratio
0
Enterprise Value
2498.38 mln
Total Assets
340.04 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Organisation
EDGEWISE THERAPEUTICS INC
Employees
108
Industry
Biotechnology
CEO
Dr. Kevin  Koch Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step